POINT Biopharma
- Founded: 2020
- Location: Indianapolis, IN
- Employee range: 50 - 200
- Clinical stage: Clin3
- Therapy area: Neuroendocrine tumors
- Drug types: ONC
- Lead product: PNT2003
- Product link: https://www.pointbiopharma.com/our-products/pipeline
- Funding: $165M Jun 2021
pointbiopharma.com linkedin.com job board
Short description:
Radioligand Therapies
Drug notes:
PNT2002 Clin3 prostate cancer; PNT2004 2 efforts Clin0/Clin1 solid tumors; PNT2001 Clin0 prostate cancer; 2+ undisclosed programs RD undisclosed
Long description:
POINT Biopharma is developing radiopharmaceutical products for cancer treatment. Radioligands are microscopic, cancer-seeking missiles that are actively used to diagnose and treat cancers such as non-Hodgkins lymphoma, neuroendocrine tumors and prostate cancer. Unlike chemotherapy that can cause extensive damage to healthy tissues and organs, radioligands precisely deliver radiation to tumors, damaging only the cancer cells. POINT is committed to accelerating the discovery, development and global access to their life-changing radioligand therapies - their lead program, SPLASH, is in Phase 3 clinical stages for treating prostate cancer.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com